title: Endocrine therapy alone vs. chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node positive breast cancer: a retrospective analysis of a multicenter study (Anatolian Society of Medical Oncology).
abstract: OBJECTIVE
  The extra benefit of adding chemotherapy to effective endocrine therapy (ET) has not been clearly or consistently identified in patients older than 70 years with estrogen receptor (ER) positive and node positive breast cancer. The aim of this study was to evaluate the efficacy of adjuvant ET vs. chemotherapy plus endocrine therapies (Chemo/ET) in such patients.
  
  
  METHODS
  In this retrospective multicenter study 191 patients ≥ 70 years with operated hormone receptor breast cancer, who were administered adjuvant ET or Chemo/ET were assessed.
  
  
  RESULTS
  The median patient follow-up time was 29.0 months (range 1-252). Therefore disease free survival (DFS) and overall survival (OS) analysis was limited, due to the rather short median follow-up, and only 30-month cumulative percentages are reported herein. The 30-month DFS rates were 50.0% in the ET arm and 49.0% in the Chemo/ET arm (p=0.79). The 30-month OS rates were 86% in the ET arm and 96.0% in the Chemo/ET arm (p=0.08). Cox proportional hazard model showed that only surgery was independent prognostic factor for survival (p=0.047), while tumor size showed a strong trend for statistical significance (p=0.051).
  
  
  CONCLUSIONS
  The addition of chemotherapy to endocrine therapy in older patients has no significant impact on DFS and OS.
authors.affiliation: Dicle University, Department of Medical Oncology, Diyarbakir, Turkey. dr.ainal@gmail.com
authors.forename: A
authors.initials: A
authors.lastname: Inal
authors.forename: T
authors.initials: T
authors.lastname: Akman
authors.forename: S
authors.initials: S
authors.lastname: Yaman
authors.forename: S
authors.initials: S
authors.lastname: Demir Ozturk
authors.forename: C
authors.initials: C
authors.lastname: Geredeli
authors.forename: M
authors.initials: M
authors.lastname: Bilici
authors.forename: M
authors.initials: M
authors.lastname: Inanc
authors.forename: H
authors.initials: H
authors.lastname: Harputoglu
authors.forename: U
authors.initials: U
authors.lastname: Demirci
authors.forename: O
authors.initials: O
authors.lastname: Balakan
authors.forename: H
authors.initials: H
authors.lastname: Yesil Cinkir
authors.forename: S
authors.initials: S
authors.lastname: Alici
authors.forename: O
authors.initials: O
authors.lastname: Uysal Sonmez
authors.forename: G
authors.initials: G
authors.lastname: Goksel
authors.forename: G
authors.initials: G
authors.lastname: Gokoz Dogu
authors.forename: O
authors.initials: O
authors.lastname: Umit Unal
authors.forename: T
authors.initials: T
authors.lastname: Tamozlu
authors.forename: S
authors.initials: S
authors.lastname: Buyukberber
authors.forename: C
authors.initials: C
authors.lastname: Melih Boruban
authors.forename: A
authors.initials: A
authors.lastname: Isikdogan
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000008:administration & dosage; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008408:Mastectomy; D009376:Neoplasms, Hormone-Dependent / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D016016:Proportional Hazards Models; D011960:Receptors, Estrogen / Q000032:analysis; D012189:Retrospective Studies; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage; D013629:Tamoxifen / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome; D014421:Turkey
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D014408:Biomarkers, Tumor; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen